{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.2568","value":"19.353"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 1 Hour Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.8350","value":"12.698"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"403"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 4 Hours Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"162.3947","value":"1.683"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"409"}],"units":"Participants"}],"title":"Cycle 1 Day 8 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"86.7699","value":"2.828"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"411"}],"units":"Participants"}],"title":"Cycle 1 Day 15 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"170.8938","value":"1.958"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"}],"units":"Participants"}],"title":"Cycle 2 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"188.6379","value":"3.217"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"394"}],"units":"Participants"}],"title":"Cycle 2 Day 8 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.2869","value":"2.252"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"391"}],"units":"Participants"}],"title":"Cycle 3 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.9781","value":"2.363"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"372"}],"units":"Participants"}],"title":"Cycle 4 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.0909","value":"2.328"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"}],"units":"Participants"}],"title":"Cycle 5 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"224.4312","value":"4.547"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"}],"units":"Participants"}],"title":"Cycle 5 Day 8 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.9349","value":"2.503"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"}],"units":"Participants"}],"title":"Cycle 6 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.9514","value":"2.585"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"}],"units":"Participants"}],"title":"Cycle 7 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.5109","value":"2.606"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"281"}],"units":"Participants"}],"title":"Cycle 8 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.1094","value":"2.566"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"269"}],"units":"Participants"}],"title":"Cycle 9 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.2494","value":"2.686"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"}],"units":"Participants"}],"title":"Cycle 10 Day 1 - Pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"423"}],"units":"Participants"}],"description":"Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG000","title":"Ixazomib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Population included all participants with at least one pharmacokinetic (PK) sample that was collected and analyzed. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)","title":"Pharmacokinetic Parameter: Plasma Concentration of Ixazomib","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}